Will 'Financial Toxicity’ Weigh Down 1L NSCLC Win For Tagrisso In India?
Executive Summary
The price factor could potentially shrink the patient pool in first line non-small cell lung cancer for Tagrisso in largely out-of-pocket markets like India, though AstraZeneca has put in place a patient assistance program in this market for those can’t afford the medicine.
You may also be interested in...
Pfizer’s Vizimpro On Course For India But Competitive Arena Awaits
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.
AZ, Pfizer, Lilly Novel Anticancers Head For India Debut
AstraZeneca’s Calquence, Pfizer’s Lorbrena and Lilly’s Verzenio, which all address unmet medical needs, have been endorsed by an expert panel in India, paving the way for their potential introduction on the market. But all eyes will be on pricing to ensure access in this largely self-pay market.
AstraZeneca's Imfinzi, Lynparza On Track To India Debut
AstraZeneca, which recently committed to scaling up investments in India, appears on course to bringing two key new anticancers to the country, including the PD-1/L1 inhibitor Imfinzi. Pricing aspects for the products in what is a largely out-of-pocket market are, however, expected to be decisive.